HUNTER SYNDROME TREATMENT MARKET ANALYSIS

Hunter Syndrome Treatment Market, by Treatment Type (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and Others), by End Users (Hospitals, Clinics, Specialty Care Unit, and Others), and by Geography - Size, Share, Outlook and Opportunity Analysis, 2022-2028

To Be Published : Oct 2024
Code : CMI1749
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Hunter Syndrome Treatment Market – Competitive Landscape

Key players operating in the global hunter syndrome treatment market include ArmaGen, Inc., BioMarin Pharmaceutical, Inc., Genzyme, Sangamo Therapeutics, a Sanofi Company, and others. Key players are engaged in developing new technologies and collaborations in order to retain dominant position in the market. For instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop AGT-182 drug for treatment of hunter syndrome.